PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL

Amplia Therapeutics reported a confirmed pathological complete response (pCR) in a patient with advanced pancreatic cancer in its ACCENT trial evaluating narmafotinib in combination with chemotherapy. The pCR, indicating no signs of cancer in surgically removed tissue, is extremely rare in advanced cases, with only around 5% of patients with locally advanced (non-metastatic) pancreatic cancer recording a pCR in response to treatment with neoadjuvant chemotherapy. The ACCENT trial is ongoing, and further updates will be provided as data accrues.

Analysis

Amplia Therapeutics (ASX: ATX) has reported a significant clinical development from its ACCENT trial, with a confirmed pathological complete response (pCR) observed in a patient with advanced pancreatic cancer being treated with its FAK inhibitor, narmafotinib (AMP945), in combination with chemotherapy. A pCR, indicating no signs of cancer in surgically removed tissue, is an exceptionally rare outcome in advanced pancreatic cancer, contrasting with the approximately 5% pCR rate seen in locally advanced, non-metastatic cases treated with neoadjuvant chemotherapy, where it correlates with improved overall survival. The ACCENT trial, a Phase 1b/2a open-label study, has completed its Phase 1b stage and is now in Phase 2a to assess efficacy endpoints including Objective Response Rate (ORR) and Duration on Trial (DOT), alongside safety. Narmafotinib is positioned by the company as a 'best-in-class' FAK inhibitor, targeting a protein increasingly recognized for its role in solid tumors, particularly fibrotic cancers like pancreatic cancer. This positive single-patient outcome, highlighted by an 'extremely positive' sentiment score (0.85) and a high market impact score (0.75), offers an encouraging sign for narmafotinib's potential.

Key Decisions for Investors

• While this single-patient pathological complete response is a highly encouraging but preliminary data point for Amplia Therapeutics' narmafotinib, investors should await more comprehensive efficacy and safety data from the ongoing Phase 2a ACCENT trial, particularly on primary endpoints like Objective Response Rate and overall cohort survival metrics.
• Given the extreme rarity of a pCR in advanced pancreatic cancer, this result could significantly enhance narmafotinib's clinical and commercial prospects if replicated across more patients; however, the high-risk, high-reward nature of clinical-stage biotechnology investments necessitates careful consideration of potential future trial outcomes.
• Investors should closely monitor upcoming trial updates from Amplia Therapeutics (ASX: ATX), as consistent positive data on ORR, Duration on Trial, Progression Free Survival, and Overall Survival will be critical for validating narmafotinib's potential and supporting the company's valuation.